601 Gateway Blvd
Ste 1250
South San Francisco, CA 94080
United States
415 910 5717
https://www.quincetx.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 21
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Dirk Thye M.D. | CEO & Director | 681.36k | N/A | 1970 |
Mr. Brendan Hannah M.B.A. | Principal Financial Officer, Principal Accounting Officer, Chief Business Officer & COO | 504.34k | N/A | 1986 |
Dr. Charles S. Ryan J.D., Ph.D. | President | N/A | N/A | 1964 |
Dr. Guenter R. Janhofer M.D., Ph.D. | Chief Scientific Officer | N/A | N/A | N/A |
Ms. Stacy Roughan | Vice President of Corporate Communications & Investor Relations | N/A | N/A | N/A |
Ms. Mary Ellen Sillivos | Vice President of Human Resources | N/A | N/A | N/A |
Dr. Stewart A. Low Ph.D. | Head of Discovery | N/A | N/A | N/A |
Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Quince Therapeutics, Inc.’s ISS governance QualityScore as of 1 March 2024 is 9. The pillar scores are Audit: 7; Board: 5; Shareholder rights: 10; Compensation: 10.